By integrating tumour purity score (TPS) into the gene expression profile, we proposed a dual therapeutic strategy: one focusing on TME interactions, particularly immune response-related components such as LILRB4, and the other targeting tumour intrinsic cellular mechanisms influenced by gene expression perspective, including transcription factors, such as GSX1 and SOX11. Here, LILRB4 is linked to neoplasm.